RECRUITING

Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Talk to us

Conditions

NeoplasmsLong Term Follow UpAdoptive Cell TherapyReplication Competent Lentivirus

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.

Official Title

Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies

Quick Facts

Study Start:2018-04-09
Study Completion:2032-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03391778

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participants who have received at least one dose of ADP adoptive cell therapy agent.
  2. * Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it.
  3. * Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy.
  4. * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  5. * The investigator is responsible for review of medical history.
  6. * Capable of giving signed informed consent.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Adaptimmune Patient Enquiries Call Center
CONTACT
215-825-9260
patients@adaptimmune.com

Principal Investigator

Adaptimmune
STUDY_DIRECTOR
Adaptimmune

Study Locations (Sites)

Emory University School of Medicine
Atlanta, Georgia, 30322
United States
ADP Investigational Site
Baltimore, Maryland, 21201
United States
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland, 20892
United States
University of Michigan
Ann Arbor, Michigan, 48109
United States
Washington University School of Medicine in St. Louis
Saint Louis, Missouri, 63110
United States
Memorial Sloan Kettering Cancer Center - New York
New York, New York, 10065
United States
Duke University Medical Center
Durham, North Carolina, 27710
United States
Oregon Health and Science University
Portland, Oregon, 97239
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
United States
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
United States
Froedtert Hospital
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Adaptimmune

  • Adaptimmune, STUDY_DIRECTOR, Adaptimmune

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-04-09
Study Completion Date2032-04-01

Study Record Updates

Study Start Date2018-04-09
Study Completion Date2032-04-01

Terms related to this study

Keywords Provided by Researchers

  • Long Term Follow Up
  • Adoptive Cell Therapy
  • Replication Competent Lentivirus

Additional Relevant MeSH Terms

  • Neoplasms